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ABSTRACT
We investigated the role of CSF1R signaling in adult
mice using prolonged treatment with anti-CSF1R anti-
body. Mutation of the CSF1 gene in the op/op mouse
produces numerous developmental abnormalities. Mu-
tation of the CSF1R has an even more penetrant
phenotype, including perinatal lethality, because of the
existence of a second ligand, IL-34. These effects on
development provide limited insight into functions of
CSF1R signaling in adult homeostasis. The carcass
weight and weight of several organs (spleen, kidney,
and liver) were reduced in the treated mice, but overall
body weight gain was increased. Despite the complete
loss of Kupffer cells, there was no effect on liver gene
expression. The treatment ablated OCL, increased
bone density and trabecular volume, and prevented the
decline in bone mass seen in female mice with age. The
op/op mouse has a deficiency in pancreatic b cells and
in Paneth cells in the gut wall. Only the latter was
reproduced by the antibody treatment and was asso-
ciated with increased goblet cell number but no change
in villus architecture. Male op/op mice are infertile as
a result of testosterone insufficiency. Anti-CSF1R treat-
ment ablated interstitial macrophages in the testis, but
there was no sustained effect on testosterone or LH.
The results indicate an ongoing requirement for CSF1R
signaling in macrophage and OCL homeostasis but
indicate that most effects of CSF1 and CSF1R mutations
are due to effects on development. J. Leukoc. Biol.
96: 265–274; 2014.
Introduction
CSF1 controls the proliferation, differentiation, maturation, and
survival of cells of the mononuclear phagocyte system [1–4]. The
effects of CSF1 are mediated through the CSF1R, a protein tyrosine
kinase receptor. Expression of Csf1r mRNA is myeloid-restricted in
adult animals, and a Csf1r-EGFP reporter gene provides a conve-
nient marker for macrophage-lineage cells in transgenic mice [5].
A natural mutation of the Csf1 gene in mice (op/op) produces
a reduction in macrophage numbers in most tissues of the body,
accompanied by severe growth retardation, osteopetrosis, and
deﬁciencies in sensory, reproductive, and other endocrine systems
[3, 4]. A null mutation of Csf1r produces even more penetrant
phenotypes, including a signiﬁcant postnatal mortality [6]. A
second ligand for CSF1R, IL-34, provides an explanation for the
greater impact of receptor depletion. IL-34 appears to be required
for the generation of speciﬁc macrophage populations, notably
microglia in the brain and epidermal Langerhans cells [7, 8].
CSF1 is not available in saturating concentrations in an adult
mouse; the concentration is regulated, in part, by macrophage-
mediated clearance in the liver and spleen, providing a relatively
simple homeostatic control of macrophage numbers [9].
Treatment of mice with CSF1 causes a massive increase in tissue
macrophage numbers throughout the body. Surprisingly, this
leads to a rapid increase in the size of the liver and hepatocyte
proliferation, suggesting a function for CSF1-dependent macro-
phages in liver homeostasis (unpublished results). Conversely,
continuous CSF1R signaling is required for the maintenance of
macrophage populations in adult mice. The administration of
a blocking mAb against the CSF1R gradually eliminated resident
tissue macrophages from many different organs. The antibody did
not prevent monocytopoiesis but apparently, prevented maturation
of monocytes in peripheral blood to form the nonclassical Ly6C2
population [10, 11]. Consequently, the treatment did not prevent
macrophage recruitment into inﬂammatory sites; indeed, the
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treatment exacerbated pathology in a model of graft-versus-
host disease. These basic ﬁndings were subsequently repeated
using a different mAb [12]. The relatively slow depletion of
tissue macrophages in the treated mice suggests that the major
effect of anti-CSF1R is to prevent their replacement, via
recruitment or local self-renewal. This view has been con-
ﬁrmed recently in models in which tissue macrophages have
been acutely depleted, and replenishment is blocked by anti-
CSF1R [13]. The slow turnover of tissue macrophages means
that after 3 weeks of treatment used previously, mice had only
been fully depleted for a short period, and the consequences
may not have become evident. Accordingly, in the current
study, we aimed to deﬁne the impact of long-term treatment
with anti-CSF1R.
MATERIALS AND METHODS
Ethics statement
All animal work was reviewed and approved by the Ethical Review Panel at The
Roslin Institute and R(D)SVS (Scotland, UK) and conducted under the
authority of Home Ofﬁce Project Licenses 60/3828 and 60/4259.
In vivo studies
M279 is a rat IgG2b mAb, which blocks CSF1 and IL-34 binding to the CSF1R.
In previous studies, the optimal dose of M279 was determined by injecting
with increasing doses, 33 weekly for 3 weeks, and serum samples taken and
assayed by ELISA for circulating CSF1. A dose of 125–400 mg/injection had
a maximal increase in circulating CSF1 [10]. Accordingly, in all of the studies
detailed herein, mice were treated with 200 mg rat anti-mouse CSF1R antibody
(M279; Amgen, Thousand Oaks, CA, USA) or rat IgG (I4131; Sigma, St. Louis,
MO, USA), administered by i.p. injection, 33 weekly for 6 weeks. MacGreen
EGFP+ and EGFP2 on the C57BL/6 background, as well as nontransgenic
C57BL/6 male and female mice, were treated, starting at 8–9 weeks of age and
weighed on each injection day. Following treatment, the C57BL/6 nontransgenic
mice were killed by CO2 asphyxiation and peripheral blood immediately
collected by cardiac puncture into EDTA tubes (K1230; Teklab, Collinsville, IL,
USA). Organs and tissues were collected and weighed, animals were eviscerated,
and a carcass weight was measured. Both femurs were collected. Bone marrow
was ﬂushed from one femur for cellularity and cell subset analysis. The other
femur was ﬁxed overnight in formalin and stored in 70% ethanol.
Flow cytometry
Bone marrow was ﬂushed from a femur from each animal, mechanically
disrupted by pipetting, counted, and diluted to 1 3 106 cells in 100 ml PBS.
Bone marrow cells (200 ml, 13106) were stained in the dark at room
temperature for 1 h at 4°C with the following antibodies: allophycocyanin anti-
mouse CD115 (CSF1R; Clone AFS98) and PerCP/Cy5.5 anti-mouse Ly-6C
(Clone HK1.4; both BioLegend, San Diego, CA, USA). Data were collected on
a CyAn ADP analyzer (Beckman Coulter, Brea, CA, USA) and analyzed using
FlowJo 7.5.5 ﬂow cytometry analysis software (TreeStar, Ashland, OR, USA)
and Minitab 16.1.0 (Minitab, State College, PA, USA).
ELISA
Blood from EDTA tubes was centrifuged at 1000 g at room temperature for
15 min. Plasma was collected and stored at 220°C. IGF1 ELISA was
preformed, according to the manufacturer’s instructions (AC-18F1; Immu-
nodiagnostic Systems, Boldon, UK).
Immunohistochemistry
Organs were collected at cull, ﬁxed in 4% PFA, and embedded in parafﬁn
wax. Testis sections for immunohistochemistry were deparafﬁnized,
rehydrated, and antigen-retrieved using a citrate buffer epitope retrieval
method [10 pounds/square inch (0.68 atmosphere), 125°C, 30 min in
citrate buffer, pH 6.0] before blocking of endogenous peroxidase and
nonspeciﬁc binding sites. For single-color immunodetection, primary anti-
bodies [anti-Mac-2, Cat. No. CL8942AP, Cedarlane, Burlington, Ontario,
Canada; CD163 (M-96), Cat. No. sc-33560, Santa Cruz Biotechnology, Santa
Cruz, CA, USA; and CD68, Cat. No. ab955, Abcam, Cambridge, UK] were
applied individually in normal horse serum and incubated at 4°C for 24 h,
followed by incubation for secondary detection [ImmPRESS reagent kit,
Cat. Nos. MP-7401 (rabbit CD163), 7402 (mouse CD68), and 7404 (rat Mac-2);
Vector Laboratories, Burlingame, CA, USA] for 1 h. Samples were washed
in TBS, and 3,39-diaminobenzidine detection (ImmPACT peroxidase sub-
strates, Cat. No. SK-4105; Vector Laboratories) was used to resolve sites of
immunolocalization, whereas hematoxylin was used as a counterstain.
Sections were then mounted for downstream analysis and visualized using
an Olympus research microscope AX70 Provis (AxioVision Rel.4.8 software;
Scotia, NY, USA).
Bones were decalciﬁed, embedded, and sectioned by the R(D)SVS
Clinical Pathology Laboratory (Scotland, UK). Postﬁxation and MicroCT
scan, femurs and tibias were decalciﬁed in 14% EDTA, pH 7.0, for 3 days at
room temperature and embedded in parafﬁn wax. Serial sections, 4 mM-
thick, were cut from each block and dried overnight at 37°C before a ﬁnal
drying at 60°C for 25 min. Sections were dewaxed in xylene, rehydrated
through ethanol, and washed. TRAP staining, using an acid phosphatase
leukocyte (TRAP) kit (387-A; Sigma), was carried out, according to the
manufacturer’s protocol, except incubation time was increased to 2 h, and
a counterstain was not used.
For detection of lysozyme in intestinal crypts, 5mM cryosections from
PFA-ﬁxed tissues were permeabilized with 50% methanol for 20 min before
immuonostaining with rabbit anti-lysozyme mAb (Abcam) and then Alexa-
Flour 594 anti-rabbit IgG (Invitrogen, Paisley, Scotland). Sections were
counterstained with Alexa-647 phalloidin (Dako, Ely, UK) and examined
using a LSM5 confocal microscope (Zeiss, Welwyn Garden City, UK).
For quantiﬁcation of goblet cells and analysis of general intestine villi
morphology, sections were treated with PAS (0.5% pararosaniline, 1%
sodium metabisulﬁte) and counterstained with hematoxylin. For dual-color
labeling of pancreas, anti-insulin antibody (Cat. No. ab7842; Abcam) was
applied at 4°C for 24 h before secondary detection (biotinylated goat
anti-guinea pig IgG antibody, Cat. No. BA-7000; Vector Laboratories).
Immunoﬂuorescence was visualized using the TSA Plus Cyanine 3 System,
Cat. No. NEL744B001KT (PerkinElmer, Waltham, MA, USA), following the
manufacturer’s instructions. Anti-pancreatic and duodenal homeobox 1
antibody (Cat. No. ab47267; Abcam) was also applied in normal horse
serum, and a secondary detection system [ImmPRESS reagent kit, Cat.
No. MP-7401 (rabbit); Vector Laboratories] was used. Finally, Cytogreen
was used as counterstain, and the sections were mounted for confocal
analysis (LSM 710, ZEN 2011 software; Zeiss).
Analysis of bone architecture by MicroCT
MicroCT analysis was performed at the left distal femoral using a SkyScan
1172 instrument set (Kontlich, Belgium) at 60 kV and 150 mA at a resolution
of 5 mm. The images were reconstructed using the SkyScan NRecon program
and analyzed using SkyScan CTAn software. A volume of 200 slices was
measured, 100 mm proximal to the primary spongiosa.
Complete blood-count analysis
Blood was collected into 0.5 ml EDTA tubes (Teklab). Total WBC, RBC, and
packed cell volume were measured on the ABX Pentra 60 hematology
analyzer. WBC differential counts were performed by making a blood smear
and counterstaining with Giemsa stain before counting.
Electrolytes
Serum electrolytes (sodium and potassium) were measured using an IL
ILab 650 analyzer (Instrumentation Laboratory, Bedford, MA, USA), using
ion-selective electrodes.
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Testosterone and LH assays
Quantiﬁcation of circulating hormones was carried out as described
previously [14, 15].
RNA extraction, labeling, and microarray
hybridization
Total RNA was extracted using TRIzol reagent (Invitrogen) from liver
tissue, homogenized in Lysing Matrix D using a FastPrep Instrument
(Q.BIOgene, Irvine, CA, USA). RNA was eluted in water, and its quality
was assessed with an 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA) before being used for labeling. Microarray was performed by
Edinburgh Genomics at University of Edinburgh (Scotland, UK). Total RNA
(50 ng) was ampliﬁed using the Pico SL kit (NuGEN, San Carlos, CA,
USA); 2.5 mg of the resulting cDNA was biotin-labeled using the NuGEN
Encore labeling kit with the one-half volume protocol. The biotin-labeled
product was prepared for hybridization, according to the NuGEN protocol
for GeneTitan hybridization, using the GeneTitan Hybridization, Wash,
and Stain Kits for whole-transcript array plates (PN 901622; both
Affymetrix, Santa Clara, CA, USA). The samples were hybridized to
Affymetrix Mouse Gene 1.1 ST array plates, using the appropriate
hybridization-wash-scan protocol for this plate and the GeneTitan
Hybridization, Wash, and Stain Kits for the reagents (Affymetrix). Image
generation and the resulting CEL ﬁles for analysis were produced in
Affymetrix GeneChip Command Console software, version 3.0.1. Initial
quality controls were performed in Expression Console. The obtained
Affymetrix CEL ﬁles were imported into the Genomics Suite software
package, version 6.13.0213 (Gene Expression Omnibus: GSE53573; Partek,
St. Louis, MO, USA).
Statistical analysis
Data on all graphs were analyzed using an unpaired t-test or Mann-Whitney
nonparametric test, as indicated. Results are presented as the mean and SEM.
All analyses were performed using GraphPad Prism 5.0 (GraphPad Software,
San Diego, CA, USA). P , 0.05 was considered signiﬁcant.
RESULTS
The effects of prolonged treatment with anti-CSF1R
mAb M279
Age- and weight-matched groups of male and female mice
were treated with M279, a blocking anti-CSF1R antibody [10],
or a rat IgG control, 33 weekly for 6 weeks. CSF1-deﬁcient
mice have severe postnatal growth retardation [3], which can
be restored by administration of CSF1 [16] and mimicked by
anti-CSF1 treatment in the postnatal period [17]. We have
shown elsewhere that CSF1-dependent macrophages are a sig-
niﬁcant source of IGF1 in the postnatal period [18]. After the
onset of puberty, the major source of IGF1 for growth is the
liver. The adult mice of both sexes continued to gain weight
regardless of anti-CSF1R treatment. Indeed, by the beginning
of week 3, weight gain in the treated mice showed a clear
acceleration relative to controls, and the faster rate of relative
weight gain continued throughout the ﬁnal 4 weeks in the
antibody-treated animals (Fig. 1A).
The efﬁcacy of the anti-CSF1R treatment was conﬁrmed as
a nearly complete reduction of Csf1r-EGFP-positive macrophages
in the spleen and intestine (Supplemental Fig. 1), extending
the ﬁndings from the shorter, 3-week treatment [10]. The
extended treatment did not produce any more extensive
depletion in sites, such as lung and uterus, in which macrophage
populations appeared independent of CSF1R signaling [10].
Some additional organs have been analyzed in detail below. In
one of the experimental series, we examined an additional
group of mice, 3 weeks after cessation of their 6-week anti-
CSF1R treatment. Surprisingly, the Csf1r-EGFP-positive macro-
phage numbers in these mice showed no evidence of recovery,
although the differential growth rate slowed (Supplemental
Figure 1. Effect of anti-CSF1R antibody on body and organ weights.
Mice were injected with 200 mg rat IgG control or M279, 33 weekly for
6 weeks. Graphs show the mean 6 SEM. Signiﬁcance is indicated by
*P , 0.05, **P , 0.01, ***P , 0.001, and ****P , 0.0001, using an
unpaired t-test; n 5 29 mice/group for body weight (bwt), and n 5
8 mice/group for organ weights. The groups were assigned to have
similar average body weights at the outset. (A) Average relative weight
gain (normalized to Day 1) taken before each injection. (B) average
spleen:body weight ratio, liver:body weight ratio, and kidney:body
weight ratio at the end of treatment. Note that absolute body weight
differences between the two groups are ,4%, so the reduced organs
weights also reﬂect absolute reductions.
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Fig. 1). However, we do not have an independent measure of the
clearance of the antibody in these mice, so we do not know
whether CSF1R signaling was restored.
At the end of the treatments, the organs and tissues of each
mouse were weighed individually. Hematological analysis
revealed a small (5–10%) but signiﬁcant (P,0.05) increase in
RBC count and signiﬁcant (P,0.01) decrease in mean red cell
volume from 48.8 ﬂ to 45.5 ﬂ. WBC counts were not altered
signiﬁcantly (Supplemental Fig. 2). After 6 weeks of anti-CSF1R
antibody treatment, the absolute weight of the liver was reduced,
mirroring the increase in liver weight seen in CSF1-treated mice
and supporting the proposed role of CSF1-dependent macro-
phages in liver homeostasis (unpublished results). Despite the
overall increase in body weight, in the male mice, there was
decrease in absolute spleen, liver, and kidney weight and organ
weight:body weight ratio. The female mice also displayed
signiﬁcant reduction in their liver weight:body weight ratio
(Fig. 1B). The increased body weight was not associated with any
change in the weight of the soleus muscle or individual fat pads
or the entire gastrointestinal tract. Indeed, there was only
a marginal increase in total carcass weight in both sexes (Fig. 2).
Hence, we conclude that the difference between the treated and
control animals is a result of an increase in blood volume and/or
body ﬂuids. There was no obvious tissue edema nor any change
in serum electrolytes (Fig. 2).
Loss of OCL and increased bone volume in anti-CSF1R
antibody-treated mice
Osteopetrosis in op/op and Csf1r-deﬁcient mice is attributed to an
almost complete deﬁciency in bone-resorbing OCL [6]. CSF1
treatment of adult mice produced a substantial increase in OCL
numbers (unpublished results) and transgenic overexpression of
CSF1 produces osteoporosis [19], indicating that OCL production/
difference remains sensitive to availability of CSF1. Bone
density in mice declines with age but more rapidly in females
[20], providing a natural and less-extreme model of osteopo-
rosis compared with the commonly applied ovariectomy
models. By the end of our experiments, the mice were 14–
16 weeks of age. To determine whether the prolonged anti-CSF1R
antibody treatment had an effect on bone, femurs from mice
were collected, ﬁxed, and analyzed by MicroCT. In keeping
with the published data, Fig. 3A shows that the BV/TV and Tb.N
were reduced by almost 50% in control female compared with
male mice. The Tb.Th of remaining trabeculae was also reduced.
In both male and female mice, TRAP-positive cells (OCL) were
almost completely ablated around the growth plates of anti-CSF1R
antibody-treated mice (Fig. 3B). In male mice, there was only
a marginal increase in bone density and trabecular volume after
6 weeks of treatment, which was not signiﬁcant. By contrast, the
femurs from female anti-CSF1R-treated mice had clear increases
in bone volume, as well as Tb.N. The impacts were visibly obvious
in sections and MicroCT images, which also showed an expansion
of the growth plate (Fig. 3C). In essence, the treated female mice
were indistinguishable from the males, suggesting that anti-CSF1R
completely prevents the age-dependent decline in bone density in
female mice. Bone growth and density are directly regulated by
circulating levels of IGF1 [21]. To investigate whether the dramatic
increase in bone volume and Tb.N of anti-CSF1R antibody-treated
females could be a result of increased IGF1, serum samples were
analyzed. Antibody-treated females demonstrated a twofold in-
crease in circulating IGF1 in their serum, whereas there was no
signiﬁcant change in the male mice (Fig. 3D). In summary, these
mouse data suggest that anti-CSF1R treatment could have
potential in preventing or reversing age-dependent osteoporosis.
Effects of anti-CSF1R in the bone marrow
As noted previously, anti-CSF1R treatment did not alter the
abundance of blood monocytes, suggesting that CSF1R signaling
Figure 2. Effect of anti-CSF1R
antibody on tissues and circulat-
ing electrolytes. Mice were
injected with 200 mg rat IgG
control or M279, 33 weekly for
6 weeks. Graphs show the mean6
SEM of the tissues indicated,
the total carcass weight after
removal of the viscera, or the
serum electrolytes. Signiﬁcance
is indicated by **P , 0.01, and
***P , 0.001, using an unpaired
t-test; n 5 6–8 mice/group.
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is not absolutely required for monocytopoiesis. The treatment
does impair development of the Ly6Clo monocyte subset
[10–12]. We wished to determine whether these effects on
monocyte differentiation actually occurred in the marrow and
also whether there was any impact on progenitors that could also
contribute to the loss of OCL. A recent report identiﬁed OCL
progenitors among the Ly6Chi monocyte-like population in
marrow [22]. The anti-CSF1R mAb-treated mice produced
a small but reproducible effect on the FSC and SSC proﬁles of
bone marrow (Fig. 4A), selectively reducing the large (FSChi),
less granular (SSClo) population by ;5%. However, the
antibody clearly ablated the Ly-6Chi/CSF1Rhi population, from
4.8% of total cells in control to only 0.5% in treated mice
(P,0.0001), which was partly balanced by an apparent
increase in the Ly6Chi/CSF1Rint in anti-CSF1R mAb-treated mice
(Fig. 4B). In summary, even prolonged treatment with anti-CSF1R
did not appear to interfere greatly with monocyte production or
maturation but may have removed candidate OCL progenitors.
Pleiotropic effects of prolonged anti-CSF1R
treatment
If anti-CSF1R is to be used therapeutically in chronic disease
situations, then it is important to consider the possible side-
effects of macrophage depletion. The op/op mouse has
a number of severe development defects, and the deletion of
the Csf1r produces perinatal lethality. We therefore wished to
determine whether any of these effects might be paralleled by a
Figure 3. Effect of anti-CSF1R antibody on bone. Mice were injected with 200 mg rat IgG control or M279, 33 weekly for 6 weeks. The right femur from
each mouse was harvested, analyzed for MicroCT scan, or prepared for histological examination, as described in Materials and Methods. (A) Graphs
show the mean 6 SEM of the BV/TV, Tb.Th, or Tb.N, determined from the MicroCT scan. (B) TRAP+ cells (blue arrows) in growth plates. (C) Two-
dimensional image (upper) and three-dimensional image (lower) of MicroCT scan from a treated (M279) and control (rat IgG) female, highlighting
expansion of the growth plate (red arrows). (D) Circulating IGF1 ELISA. Signiﬁcance is indicated by *P , 0.05, **P , 0.01, and ****P , 0.0001, using
an unpaired t-test.
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continuing requirement for CSF1R signaling in the adult. One
of these effects of CSF1 deﬁciency is the loss of pancreatic b
cells and insulin production [23]. However, the prolonged anti-
CSF1R treatment, which ablates macrophage populations in the
pancreas and adipose tissue all over the body [10], had no
effect on average size or b-cell distribution within islets of
Langerhans detected by immunostaining for insulin (Supple-
mental Fig. 3).
The op/op mouse and Csf1r-deﬁcient mice also have substan-
tial defects in intestinal proliferation and differentiation,
including a loss of leucine-rich repeat-containing G protein-
coupled receptor 5-positive epithelial progenitors and of Paneth
cells [24–26]. Although these effects have been attributed to
direct roles of CSF1 on epithelial cells, the Csf1r-EGFP
transgene is not detectable in the crypts. Csf1r-EGFP-positive
macrophages are abundant in the lamina propria and in
intimate contact with these structures (Supplemental Fig. 1).
Following prolonged treatment with anti-CSF1R, the Paneth cell
density within crypts of Lieberku¨hn, highlighted by staining of
lysozyme, was reduced substantially (Fig. 5A and B). Conversely,
and in keeping with the phenotype of the op/op mouse [24–26],
there a small increase in goblet cell density, identiﬁed by PAS
staining (PAS+ cells; Fig. 5C). Despite these changes and the
complete loss of the abundant Csf1r-EGFP-positive macrophage
population from the lamina propria (Supplemental Fig. 1),
there was no evidence of deﬁcient epithelial renewal. Average
villus length was marginally reduced in anti-CSF1R-treated mice,
whereas villus width (combined mean of three cross-sections
of each villus from top, bottom, and middle) was unchanged
(Fig. 5D).
The op/op mouse is both male- and female-infertile [3, 4]. In
female mice, the antibody did not deplete Csf1r-EGFP-positive
macrophages from the ovary or uterus. We also examined the
estrous cycle stage of the female mice when they were killed and
noted a range of cycle stages. It is possible that the treatment
would alter the duration of the cycle, but this has not been
tested systematically. We focused instead on the male mice. The
op/op mouse has deﬁcient testosterone production, lower levels
of LH, and a failure of the normal testosterone-feedback
pathway in the hypothalamus [27, 28]. Other approaches
to macrophage depletion support a role for macrophages in
Leydig cell function [29]. Three-week treatment with anti-CSF1R
completely ablated the interstitial macrophages, as detected with
the Csf1r-EGFP transgene [10]. There was signiﬁcant reduction in
testis weight following the prolonged 6 weeks of anti-CSF1R
antibody treatment (Fig. 6A). The ﬁxation required for ultra-
structural preservation precludes the use of the Csf1r-EGFP
transgene directly for localization, so immunohistochemistry was
used. The complete removal of macrophages in the testicular
interstitium by prolonged anti-CSF1R treatment was conﬁrmed
using Mac-2 or CD163 anti-macrophage antibodies (Fig. 6B).
Nevertheless, the testicular architecture and spermatogenesis
appeared completely unaffected by ablation of the macrophages.
To assess speciﬁcally the impact on Leydig cell function, we
assayed circulating hormones. There was no difference in either
circulating testosterone or LH concentrations (Fig. 6C), and
seminal vesicle weight, a biomarker of androgen signaling, was also
unchanged between control and treated animals (Fig. 6A).
Lack of anti-CSF1R antibody toxicity and pathology
Despite the drastic decrease in resident tissue macrophages in
many of the organs of the anti-CSF1R antibody-treated mice,
H&E sections of skin, small intestine, pancreas, lung, liver,
kidney, and spleen revealed no overt pathology (data not
shown). In light of the loss of macrophages in the gut and liver,
we considered the possibility that there would be exposure of the
liver cells to contents from the gut or other impacts on liver cell
function. Aside from the regulation of hepatocyte proliferation
described previously, Kupffer cells have been ascribed many roles
in clearance and protection of the body from potentially toxic
metabolites in the portal blood [30]. Gene-expression arrays
were used to determine whether there were any changes in
hepatic gene expression associated with the evident decrease in
macrophages. In the entire dataset comparing replicated treated
and untreated samples, there were no transcripts that were
differentially increased by .1.5-fold at an adjusted P value of 0.05.
Kupffer cells are a relatively small proportion of total mRNA in the
liver, and macrophage-speciﬁc transcripts are on the boundaries
of detection. We examined the array data for evidence of
Figure 4. The effect of prolonged anti-CSF1R treatment on bone marrow cells. Representative FACS proﬁles of bone marrow cells derived from control
rat IgG or anti-CSF1R treated mice. (A) FSC/SSC proﬁles highlighting the selective loss of the population of large cells with relatively low SSC (arrows).
(B) CSF1R/Ly-6C proﬁles highlighting an almost complete loss of cells with high-surface CSF1R and Ly6C (arrows).
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depletion of macrophages. Transcripts, such as Cd163, Csf1r,
Siglec1 (which encodes sialic acid-binding Ig-like lectin 1), and
those encoding class II MHC (H2-Ab1) and Emr1 [which
encodes epidermal growth factor-like module containing
mucin-like receptor 1 (F4/80)], showed a decline of ;50%
(P,0.05; Supplemental Fig. 4). The residual activity is likely
a result of monocytes and granulocytes in the blood, as these
livers were not cleared before removal into Trizol.
DISCUSSION
This study extends our earlier report on the impact of treatment
of mice with a blocking anti-CSF1R antibody [10]. The
prolonged treatment uncovered physiological impacts of mac-
rophage depletion of clinical relevance, notably the acceler-
ated weight gain after 3 weeks (Fig. 1) and the prevention of
bone loss (Fig. 3). But even after the 6 weeks of macrophage
depletion, some functions that are deﬁcient in the op/opmouse
were unaffected. As discussed in detail elsewhere [3], the M279
antibody used here has subtly different effects from the more
widely used AFS98 rat-anti mouse CSF1R antibody. A previous,
prolonged study using AFS98 was carried out in the context of
diabetes in the db/db mouse, where 6 weeks of treatment was
beneﬁcial in preventing renal pathology, but the impact on
the control mice was not tested [31]. Both antibodies block
CSF1 and IL-34 binding with high afﬁnity, but AFS98 causes
much more rapid depletion of tissue macrophages, possibly via
direct toxicity [3]. Many companies have produced small
molecule inhibitors of CSF1R kinase activity; and most of these
have been claimed to be highly speciﬁc [3]. However, given
the high level of conservation of the tyrosine kinase domains
of the type III protein tyrosine kinases (CSF1R, Fms-like
Figure 5. Effect of anti-CSF1R treatment on Paneth
and goblet cells of the intestine. (A) Four-percent,
PFA-ﬁxed, 5 mm cryosections of ileum from control
(rat IgG) or anti-CSF1R-treated (M279) mice were
immunostained to detect lysozyme (red) in granules
of Paneth cells within intestinal crypts, counterstained
with F-actin (blue); original scale bars, 50 mm. (B)
Morphometric analysis was performed to identify the
proportion of crypts with Lysozyme+ staining, pro-
portion of Lysozyme+ cells within Lysozyme+ crypts,
and overall immunolabeling of lysozyme within crypt
regions. Graphs show the mean 6 SEM for the
comparative difference between control (rat IgG) and
anti-CSF1R (M279) treatment. Signiﬁcance is indi-
cated by *P , 0.05, and ***P , 0.001, as determined
by Mann-Whitney U-tests. Twenty villi/mouse were
counted (n58 mice). (C) Four-percent, PFA-ﬁxed,
5 mm parafﬁn-embedded sections were analyzed for
positive PAS staining for goblet cells in control (rat
IgG) and anti-CSF1R-treated (M279) mice. (D) Ileal
intestine sections. Morphometric analysis was per-
formed to analyze PAS+ cells/100 mm villus; average
ileal villus length and average villus width.
Sauter et al. Effects of anti-CSF1R treatment in mice
www.jleukbio.org Volume 96, August 2014 Journal of Leukocyte Biology 271
tyrosine kinase-3, KIT, platelet-derived growth factor recep-
tor), it would be difﬁcult to predict off-target impacts in vivo,
based on the in vitro data. The anti-CSF1R antibody effects can
potentially provide the benchmark for effects that are likely to
be genuinely on-target, as well as a potential therapy in its own
right. The relatively slow depletion of macrophages seen with
anti-CSF1R treatment suggests immediately that efﬁcacy in
a clinical scenario would require sustained treatment.
The deﬁnitive phenotype of the CSF1-deﬁcient mouse is
osteopetrosis, as a result of a complete lack of OCL [6, 32].
Additionally, toothless (tl/tl), a CSF1 null mutation in the rat,
has few OCL and undetectable bone resorption, and the
phenotype can be reversed with exogenous CSF1 [33]. In
humans, variation at the CSF1 locus has been implicated in
bone loss in Paget’s disease [34]. Many different CSF1R kinase
inhibitors have been tested on various mouse disease models
with some effect on bone: JNJ-28312141 prevented tumor-
induced osteoclastogenesis and bone erosion [35]; Ki20227
inhibited osteolytic bone destruction through the suppression
of CSF1-induced OCL accumulation in vivo [36]; SU11248
caused in vivo inhibition of osteolysis [37]; and one of the most-
used CSF1R inhibitors, GW2580, completely inhibited bone
degradation in cultures of human OCLs, rat calvaria, and rat
fetal long bone [38]. More recently, yet another inhibitor,
PLX3397, attenuated osteoclastic bone resorption in a model of
neuroﬁbromatosis [39]. None of these studies has applied
treatment to natural age-associated bone loss in mice, and all
have potential off-target effects via other kinases. Figure 3 shows
that anti-CSF1R treatment completely ablated the TRAP-positive
OCL populations in mouse bone and greatly reduced their Ly6Chi,
CSF1Rhi candidate progenitors (Fig. 4). The loss of OCL did
not greatly increase bone density in male mice, suggesting that
the impact is balanced by a decrease in bone formation.
Paradoxically, like anti-CSF1R, CSF1 treatment of mice can also
increase bone density, despite increased OCL number (un-
published results) perhaps because of the interaction between
bone-lining macrophages and osteoblasts [40, 41]. However,
anti-CSF1R treatment completely prevented the substantial
decrease in bone density seen in the female mice. The effect
could be partially a result of the increased, circulating IGF1
(Fig. 3), although the levels of IGF1 in controls were the same in
males and females and therefore, not correlated to bone density.
Local and systemic human rIGF1 treatment increased new bone
formation [42]. Anti-CSF1R treatment has been considered as
a means of removing macrophages from tumors [10]; an impact of
treatment upon hypercalcemia of malignancy [43] could be
a secondary beneﬁt. It will be of some interest to determine
whether, like antibodies against the receptor activator of NF-kB
ligand, anti-CSF1R can block glucocorticoid-induced bone
loss [44].
Aside from the impacts on bone, the prolonged anti-CSF1R
treatment was surprisingly well-tolerated. Where anti-CSF1
treatment has been shown to impair postnatal somatic growth
[17] and CSF1 treatment to promote it [45], the treatment
of the sexually mature, young-adult mice with anti-CSF1R
did not compromise their continued weight gain. So, the
CSF1-dependent phase of somatic growth occurs before the
liver becomes the major source of IGF1 at sexual maturity.
Anti-CSF1R did reduce the size of the liver, thereby
supporting our hypothesis that CSF1 contributes to the
homeostatic regulation of liver size (unpublished results)
and consistent with the report that the op/op mouse cannot
regenerate the liver following partial hepatectomy [46].
We do not have an explanation for the apparent
Figure 6. Effect of anti-CSF1R treatment on the testis. Mice were injected with 200 mg rat IgG control or M279, 33 weekly for 6 weeks. Serum was
collected, as well as tissue, which was ﬁxed and processed as described in Materials and Methods. Graphs show the mean 6 SEM. Signiﬁcance is indicated
by *P , 0.05, using unpaired t-tests. (A) Testis and seminal vesicle weight. (B) Representative sections show macrophages within the testicular
interstitium, stained with a macrophage marker, Mac-2 or CD163. (C) Serum levels of testosterone and LH.
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ﬂuid accumulation in the treated mice, which did not appear
to be associated with any overt pathology.
Several other reported phenotypes of the CSF1 and CSF1R-
deﬁcient mice probably reﬂect nonredundant roles of macro-
phages in development rather than homeostasis. For example,
we saw no effect of anti-CSF1R on b-cell number in the
pancreatic islets (Supplemental Fig. 3). The close physical and
functional relationship between testicular macrophages and
Leydig cells in control of testosterone production is well-
described. One of the major roles of macrophages under
normal circumstances is to generate and provide 25-hydroxy-
cholesterol as a substrate for steroid hormone production [29].
The impact of the op/op mouse implicates CSF1 as a key factor
in male and female reproductive development [27–29, 47].
Our data now suggest that macrophage support of steady-state
testis steroidogenesis in adulthood is largely dispensable or at
least can be compensated through the LH/testosterone
feedback.
The op/op mouse also has deﬁciencies in intestinal differenti-
ation [24–26]. These reports identiﬁed numerous alterations in
villus architecture, resembling the morphology of the villi
reported in patients with malabsorption and lipid-engorgement
disorders. The appearance of the mutant villi was also abnormal,
and the average number of cells/crypt and cells/villus was
reduced signiﬁcantly in both mutants. Such pathologies would be
of signiﬁcant concern in the application of anti-CSF1R treatment.
However, whereas the prolonged treatment greatly reduced the
numbers of Paneth cells and produced a small increase in goblet
cell number, there was no sign of altered villus architecture. The
intestinal phenotype in the op/op mouse has been attributed to
expression of CSF1R within the villus. In one study, Csf1rﬂ/ﬂ were
crossed to mice expressing a tamoxifen-inducible Cre transgene
driven by an intestine-speciﬁc promoter (VillinCreERT2).
Tamoxifen treatment produced slow ablation of the Paneth cells.
These studies did not include a control with an irrelevant Cre
target gene other than Csf1r, so direct effects of overexpression of
Cre recombinase on stem-cell proliferation and/or survival
cannot be eliminated. The Csf1r-EGFP reporter gene is not
expressed at all in the crypt, but macrophages are in intimate
contact with the basement membrane (Supplemental Fig. 1).
Furthermore, analysis of the large gene-expression datasets
produced by the FANTOM5 consortium [48] indicates that there
is no detectable expression of Csf1r mRNA within isolated crypts.
Although CSF1 has been reported to promote clonogenic growth
of murine colonic crypt preparations [49], the more recent
studies on the colon also argue that CSF1 acts indirectly to
promote colonic enterocyte proliferation [25]. Accordingly, we
suggest that the effect of the anti-CSF1R antibody on Paneth cells
is an indirect consequence of the depletion of the lamina propria
macrophages.
Others have claimed that the CSF1R is expressed functionally
in subsets of neurons [50] and in renal proximal tubule cells
[51]. In both cases, CSF1 has been attributed to roles in
regeneration and/or cytoprotection. As in the intestine, these
claims are not supported by the pattern of expression of the
Csf1r-EGFP transgene [5] nor is Csf1r mRNA expression
detected in isolated neurons, crypts, or any puriﬁed epithelial
cells based on deep 59RACE-tag sequencing of mouse or
human [48]. We saw no effect of systemic anti-CSF1R treatment
on microglial cell numbers in the brain nor any apparent effect
on renal architecture, despite the complete loss of the large
interstitial macrophage population.
In conclusion, our studies suggest that many of the effects of
Csf1 and Csf1r mutations reﬂect development roles that are
redundant or functionally compensated in an adult mouse. The
effect on bone turnover suggests that the treatment could have
potential in the treatment of osteoporosis and may be well-
tolerated. Of course, the important caveat to this study is that
macrophages are an important component of the innate
immune system and immune homeostasis. There is the potential
to make inﬂammatory processes considerably worse with anti-
CSF1R treatment [10]. So, there is a need to explore further the
impacts of this treatment on host defense.
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